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4 SUMMARY 
Treatment for a chronic disorder may be regarded as a part of the environmental influences, 
but is not commonly looked upon as such. Although inhaled corticosteroids (ICS) for the last 
decades have been the treatment of choice for mild persistent to severe persistent asthma in 
accordance with the guidelines, little is known especially from long term studies regarding 
possible modifying effects of early ICS treatment on development of asthma in children. 
Understanding how treatment influences development of later asthma has important 
implications for prevention of the disease.  
After several decades with an increase in prevalence of asthma in the Western world, some 
recent reports suggest that prevalence of childhood asthma has reached a plateau in some 
European countries. Some studies, on the other hand, have found a steady rise in the 
prevalence rates. 
Although there is evidence to show that severe asthma in childhood tends to persist in 
adulthood, it is not well known whether severity of obstructive airways disease (OAD) in 
early life has impact on later asthma, the understanding of which may improve follow-up of 
children with high risk for persistent asthma.  
Aims of the thesis: 
The main objective of the present thesis was to assess if early treatment with inhaled 
corticosteroids could modify disease progression in childhood.  
1. To investigate the prevalence of recurrent bronchial obstruction (rBO) and asthma in 
children in a general urban population. 
2. To determine how often inhaled corticosteroids were used for treatment of obstructive 
airways disease in childhood.   
3. To assess if ICS treatment had an effect on lung function in young children with 
recurrent bronchial obstruction (rBO).  
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4. To define a severity score for severity of obstructive airways disease during the first 
two years of life and assess if the severity score can be used as a tool to predict 
asthma in school children. 
5. To explore if early ICS treatment in children with obstructive airways disease during 
the first two years of age can modify occurrence of current asthma in school children. 
Study design 
The present study is part of a 10 year follow-up of children in the prospective birth cohort, 
the Environment and Childhood Asthma (ECA) study in Oslo. Briefly, a cohort of 3,754 
children was established at birth in Oslo in 1992. The study design had three main phases. 
The initial phase was to obtain background information including family history of diseases, 
environment, and clinical characteristics of the newborn baby as well as lung function 
measurements shortly after birth in 803 children. The second phase covered the first 2 years 
of life which included questionnaires, and a nested case-control study at 2 years including 
children with physician confirmed recurrent (>1) bronchial obstruction (rBO) or persistent 
bronchial obstruction (>4 weeks) (n=306) and age-matched controls (n=306). The third phase 
was the 10 year follow-up study attended by 1019 of 1215 children (84 %) with lung function 
measurements at birth and/or a clinical two-year investigation.  
Subjects and methods  
For aim 1 (to investigate the prevalence of recurrent bronchial obstruction by two years of 
age) and aim 2, all children from the entire cohort (3697 of 3754 with complete questionnaire 
data by two years of age) who had completed all five follow-up questionnaires as well as all 
children defined with rBO who had attended at least one visit were assessed. To assess the 
prevalence of asthma by 10 years of age, the 616 of 803 subjects who had lung function 
measurements performed shortly after birth were reinvestigated at the age of 10 years with 
detailed clinical examinations including parental interview, lung function measurements and 
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skin prick test (paper I). At birth, they corresponded to the entire birth cohort of 3754 
children. History of asthma, asthma during the last 12 months, and allergic skin sensitization 
at 10 years of age were assessed.  
For aim 3, 54 children with rBO (with and without ICS treatment) and 15 controls with tidal 
flow volume measurements upon presentation of disease (mean age 11 months) and two 
years of age were studied (paper II).  
For the aims four and five, 459 subjects (239 and 220 with and without rBO, respectively at 
two years of age) from the nested case control study who attended 10 year follow-up and 
underwent clinical examination, parental interview, treadmill test and bronchial hyper 
responsiveness test to methacholine were studied. A severity score at two years of age was 
calculated by frequency, persistence of symptoms of bronchial obstruction and hospital 
admissions due to OAD and was used to predict asthma at 10 years of age (paper III). The 
same study population was studied to assess the risk of current asthma at 10 years of age in 
children who received ICS compared to those who did not by two years of age (paper IV).  
Results  
Recurrent bronchial obstruction or asthma in children 
Of all healthy children enrolled at birth in the study (3697 of 3754 with complete 
questionnaire data by two years of age), 306 subjects had documented symptoms of recurrent 
bronchial obstruction by two years of age, corresponding to prevalence of 8.3 % with rBO in 
young children. 
In 10-year-old children, the lifetime prevalence of asthma was 20.2 %, current asthma 11.1 
%, doctors’ diagnosis (as reported by the parents) of asthma 16.1 %, wheeze ever 30.3 % and 
allergic skin sensitization 29.3 % at 10 years of age. Our finding of 20.2 % lifetime 
prevalence of asthma among 10 year old children represented the highest number ever 
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reported in Scandinavia by year 2005. However, the increase in asthma prevalence was not 
accompanied by parallel increase in allergic skin sensitization. 
Use of inhaled corticosteroids in young children 
From the entire cohort (3697 of 3754 with complete questionnaire data by two years of age), 
77 children corresponding to a prevalence of 2.1 % and 64 (21 %) of children with rBO had 
received ICS treatment by two years of age.  
Effect of inhaled steroids on lung function in young children 
Baseline lung function assessed by tidal breathing (the ratio of time to peak expiratory flow 
to total expiratory time (tPTEF/tE)) at the debut visit was significantly lower in children who 
later received ICS as compared to those who did not, but there were no significant 
differences between the treatment groups in baseline lung function at the two year visit. The 
mean difference in baseline tPTEF/tE (change from first to second visit) was significantly 
higher (borderline) in the ICS-treated group only and correlated significantly with duration of 
ICS treatment.  
Impact of severity in early life on later asthma 
Severity score at two years of age was significantly higher among rBO children who 
developed current asthma at 10 years of age compared to rBO children without current 
asthma (5.5, 4.9-6.1 versus 4.0, 3.6-4.5, respectively, p<0.001). Receiver operated 
characteristic (ROC) analysis, positive and negative predictive values demonstrated the 
applicability and value of the severity score with optimal cut off value at six. Furthermore, 
children with severity score above five had more often severe bronchial hyperresponsiveness 
(BHR) than children with a lower or 0 score (22.2 % versus 8.5 %, respectively, p=0.0041). 
The risk (odds ratio, 95 % confidence intervals) of current asthma among rBO subjects when 
compared to no BO subjects was 7.9, 4.1-15.3 whereas the risk of current asthma among rBO 
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subjects with severity score above five was 20.2, 9.9-41.3 compared to no BO children.  
Impact of early ICS treatment on the prognosis of asthma 
ICS treatment in the first two years of life did not reduce the risk of current asthma eight 
years later in our observational birth cohort study. Propensity modeling was used to 
compensate for non-randomness and adjust for severity of disease at two years of age. In rBO 
children logistic regression analyses identified male gender and severity score at two years as 
significant risk factors for current asthma at 10 years of age, whereas the use of ICS 
treatment before two years of age was not significantly (borderline) associated with current 
asthma at 10 years of age.  
Conclusions 
1. Recurrent bronchial obstruction was seen in 8.3 % children in the present prospective 
birth cohort by two years of age.  
Furthermore, every fifth 10 year old child in the city of Oslo at some time had 
asthma. 
2. The use of ICS (as reported by parents) corresponded to 2.1 % of all children in the 
cohort study and 21 % of children with rBO by two years of age.  
3. Lung function appeared to improve in children using ICS from the start of symptoms 
of OAD until two years of age, mostly in children with the longest duration of 
treatment.   
4. A scoring system based on severity and frequency of obstructive airways disease 
during the first two years of life predicted current asthma at 10 years of age.  
5. Use of ICS during the first two years of life in children with obstructive airways 
disease did not reduce asthma present eight years later.  
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5  REVIEW OF THE LITERATURE 
5.1 History of asthma 
 
The actual term asthma is a Greek word that is derived from the verb ααζειν (aazein), 
meaning to exhale with open mouth, to pant (1). The expression asthma appeared for the first 
time in Homer’s Iliad (1), with the meaning of a short-drawn breath, but the earliest text 
where the word is found as a medical term is the Corpus Hippocraticum in 450 BC (1). 
Hippocrates thought that the spasms associated with asthma were more likely to occur in 
tailors, anglers, and metalworkers. Six centuries later, Galen wrote much about asthma, 
noting that it was caused by partial or complete bronchial obstruction. In 1190 AD, Moses 
Maimonides, an influential medieval rabbi, philosopher, and physician, wrote a treatise on 
asthma, describing its prevention, diagnosis, and treatment (2). In the 17th century, 
Bernardino Ramazzini noted a connection between asthma and organic dust. Its status as a 
modern disease, however, dates to the autopsy series of the Paris hospitals in the 1810s, 
where bronchial asthma, cardiac asthma, and other forms of shortness of breath were 
redefined as pathological entities. Asthma was treated with a variety of available remedies 
from morphine to tobacco in the nineteenth century to steroids and beta-agonist inhalers in 
the twentieth. The use of bronchodilators started in 1901, but it was not until the 1960s that 
the inflammatory component of asthma was recognized, and anti-inflammatory medications 
were added to the management.  
5.2 Asthma description 
Asthma is a chronic disorder defined by its clinical, physiological and pathological 
characteristics, but since the aetiology and pathogenesis is not entirely known, much of its 
definition is descriptive. Based on the functional consequences of airway inflammation, an 
operational description of asthma according to Global initiative for asthma (GINA) (3) is: 
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“Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular 
elements play a role. The chronic inflammation is associated with airway hyper 
responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, 
and coughing particularly at night or in the early morning. These episodes are usually 
associated with widespread, but variable, airflow obstruction within the lung that is often 
reversible either spontaneously or with treatment.” Asthma is characterised by relapsing 
nature of symptoms occurring either spontaneously or in response to external stimuli. The 
disease has a varying natural history, ranging from a transient disease of childhood through to 
persistent severe disease throughout life.  
5.3 Asthma in children  
Asthma is the most common chronic disease among children, and the most frequent cause of 
hospital admissions in childhood (4;5). The disease has great bearings on the individual 
suffering from the disease, their family as well as for the society at large. The large increase 
in asthma seen worldwide over the last decades has recently been characterized as an 
epidemic (6), with causes largely unknown. In a recent publication from International Study 
of Asthma and Allergies in Childhood (ISAAC) Phase-III conducted worldwide, Asher and 
co-workers (7) reported increasing prevalence of asthma in 6-7 year old children compared to 
13-14 year age-group during the five year period (1997-2002-3). The majority of 
participating centres in this global study reported increased asthma prevalence in childhood 
(7). Pearce and co-workers (8) using ISAAC questionnaires found increases in asthma 
prevalence in Africa, Latin America, and parts of Asia indicating that the global burden of 
asthma is continuing to rise. The same study, however showed decreases in asthma 
prevalence in English speaking countries and Western Europe and increases in prevalence in 
regions where prevalence was previously low (8). Ait Khaled and co-workers (9) found that 
urbanized centers in African countries reported higher prevalence of asthma similar to that of 
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Westernized nations, with considerable variations in the prevalence rates between the 
reporting centers within the same country and between the countries. 
Wheezing phenotypes and asthma in preschool children 
The onset of asthma commonly occurs during the preschool years (10). However, the 
identification of children with asthma remains problematic in preschool age group (11). The 
clinical syndrome we recognize as asthma in school age does not develop in all infants and 
children with wheezing illnesses.  
Diagnosis of asthma in preschool children is particularly difficult as viral induced episodic 
wheezing commonly occurs in children younger than three years of age. Three categories of 
wheezing have been described for children;  
1) Transient early wheezing is often limited to the first three years with no symptoms 
later in life. Transient wheezing is often associated with prematurity and parental 
smoking. 
2) Persistent early-onset wheezing: Symptoms usually begin before three years of age 
persisting into school age. The children have recurrent episodes of wheezing 
associated with acute respiratory viral infections, but no evidence of atopy or family 
history of atopy.  
3) Late onset wheezing/asthma: Children have asthma that often persists throughout 
childhood into adult life. They usually have an atopic background, often with eczema, 
and airway pathology that is characteristic of asthma. 
These wheezing phenotypes are retrospectively categorized partly based on lung function 
parameters and are used widely for epidemiological research (12). However, these asthma 
phenotypes are of limited help in caring for an individual patient in clinical practice. 
Recently, a report (13) studying characteristics of wheezing in 12-59 months old children has 
identified a subgroup with severe intermittent wheezing characterized by atopic features and 
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substantial illness-related symptom burden despite prolonged periods of wellness.  
Differences between adult and childhood asthma  
The pathology of asthma is often less progressed in children; with a smaller degree of airway 
remodelling that may be reflected in differing responses to treatment (14). Furthermore, 
asthma in childhood is generally less severe than in adults, with intermittent and mild 
persistent disease characterising the majority of patients (14). However, paediatric asthma is 
frequently associated with atopy (the predisposition to develop immunoglobulin-E against 
specific allergens) and other atopic diseases like eczema and rhinitis.  
Apart from difficulties in diagnosing asthma in preschool children, major challenges in 
paediatric asthma include development of methods of easily assessing lung function and non-
invasive methods of assessing inflammation in asthmatic children.  
Asthma from childhood to adulthood  
Burrows and co-workers (15) have hypothesized as early as in 1977 that paediatric 
respiratory illness represents an important risk factor for the development of obstructive 
airway diseases in adult life. It is suggested that these childhood respiratory illnesses cause 
the adult lung to be unusually susceptible to the adverse effects of a variety of bronchial 
irritants and infectious agents (15). Other studies (16;17) have confirmed these findings. 
Godden et al (16) found that the subjects who had asthma in childhood were more likely to 
wheeze in adult life. Similarly, in an unselected birth cohort from Dunedin, New Zealand, 
more than 25 % who had wheezing in childhood persisted in to adulthood or relapsed after 
remission until age 26 years (17). The factors predicting
 
persistence or relapse were 
sensitization to house dust mites,
 
airway hyperresponsiveness, female sex, smoking, and 
early age
 
at onset (17). It is therefore suggested that the outcomes in adult asthma may be 
determined primarily in early childhood (15-17). Segala and co-workers (18) found that 
asthma beginning in childhood and relapsing in adulthood had greater frequency of asthma 
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attacks, earlier onset of allergy and more obstructed airflow than those with adult-onset 
asthma.  
5.4 Prevalence of childhood asthma  
The prevalence of asthma symptoms in children varies from one to more than 30 % in 
different populations and is increasing in most countries, especially among children (7). The 
highest prevalence has been reported in English speaking countries (Australia, New Zealand, 
and England) and lower levels in Scandinavian countries (19). A Norwegian cross-sectional 
study (20) using ISAAC questionnaires has shown prevalence of asthma to be 13.8 % in 9-11 
year old children during the year 2000, slightly increased from 13.2 % during the year 1995. 
In the last mentioned study, increase in prevalence of asthma was observed only in boys 
while it reached a plateau in girls during the period 1995-2000. On the other hand, an another 
Norwegian study (21) showed significantly more prevalent asthma among girls compared to 
boys. In the latter study, asthma was reported by 8.5 % and 12.2 % among girls and 7.1 % 
and 7.0 % among boys in the age group 13-16 and 17-19 years, respectively. Burr et al (22) 
from a study of 12 year old British school children reported continued increased prevalence 
of asthma ever to 27.3 % and current wheeze to 19.7% during the year 2003. 
Physician diagnosed asthma varies considerably from country to country, with UK study (23) 
reporting highest levels (around 21%) to 4-7% in a Finnish study (24) during mid-1995-1997. 
In the studies of Norwegian school children, physician diagnosed asthma was around 8-9%  
(25-28) while it was only 5.1% in Russian children bordering to Scandinavia during 1994-5 
(29). 
‘Wheeze ever’ was reported in 11% Norwegian children in Oslo (28) and 13-20 % in Finnish 
children (24) while it was significantly higher (49%) in British children (30). In a recent 
Norwegian study by Tollefsen et al (21), current wheeze was reported by 29.0 % and 33.5 % 
of girls and 20.4 % and 22.1 % of boys in the age group 13-16 and 17-19 years, respectively.  
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Recent reports from some European countries (31;32) suggested that a plateau was reached 
regarding rates of childhood asthma prevalence, after several decades with an increase of 
asthma observed in the Western world (33;34). On the other hand, some studies (35;36) have 
found increases in asthma prevalence, during the periods from 1986-2001 in 7-17 year old 
Danish children (35) and 1992-1999 in 5-14 year old German children (36).  
It should be noted that all the above mentioned studies are cross-sectional surveys as there is 
limited knowledge available from prospective cohort studies. 
5.5 Early risk factors for later asthma in childhood 
The majority of children with asthma have asthma-like symptoms during the first few years 
of life (37;38). However, predicting asthma in school age from wheezing illness in early life 
is challenging since the aetiology of wheezy lower respiratory tract disease and the outcomes 
differ in early childhood (12;39;40).  
Several studies (41-43) have found association with development of childhood asthma and 
parental history of asthma and/or allergic rhinoconjunctivitis. Bener et al (41) have shown 
that history of asthma in father, mother, siblings and asthma in second degree relatives were 
significant predictors for paediatric asthma. Furthermore, longitudinal studies (43;44) have 
shown that personal history of allergic rhinitis, atopic dermatitis and allergic sensitization 
especially to house dust mites, were independent risk factors for the development of 
childhood asthma. Kulig et al (45) from the German birth cohort, the MAS study found that 
persistent food sensitization in combination with a positive atopic family history was a strong 
predictor for the development of asthma and allergic rhinitis at five years of age. Moreover, 
food allergy has been implicated as a strong risk factor for later asthma life-threatening 
asthma in children (46). 
There is now convincing evidence that children who develop lower respiratory symptoms 
during infection with respiratory syncytial virus (RSV) in early life are at increased risk of 
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developing asthma-like symptoms later in life (47-49). Furthermore, in children born into 
asthmatic/atopic families, viral exposures in early life were associated with asthma symptoms 
(50), especially symptomatic rhinovirus illnesses (51).  
There is strong evidence for a causal relationship between environmental tobacco smoke 
exposure and asthmatic symptoms (52-54), whereas the evidence between environmental 
tobacco smoke exposure and development of allergy was much weaker (52). A  prospective 
birth cohort study (55) demonstrated that the residential dampness problems increased the 
risk of bronchial obstruction in young children. Similarly,  Pekkanen et al (56) in a 
population-based case control study found that moisture damage and mould growth in the 
main living quarters were associated with the development of asthma in early childhood.  
The mechanism of BHR in early childhood and later development of asthma is not yet well 
known. In a study by Saga et al (57), bronchial reactivity to inhaled methacholine during the 
infantile period was studied using the transcutaneous partial pressure of oxygen method and 
children were followed 10 years for the development of asthma. They found that infants with 
a clinical diagnosis of bronchiolitis or wheezy bronchitis and who showed BHR in the 
infantile period, had increased risk of later asthma (57).  
Risk factors as predictors 
Although risk factors for development of childhood asthma were extensively studied, only 
few studies (58;59) have focused on using risk factors to predict later asthma.  
From the Tucson Children’s Respiratory Study, Castro-Rodriguez and co-workers (58) 
developed two clinical indices at three years of age to define risk of asthma in school age. 
Their indices included six parameters (frequency of wheezing during the first three years of 
life, history of eczema, parental history of asthma, eosinophilia, allergic rhinitis and 
wheezing without colds). They found active asthma on at least one time-point between 6-13 
years in 76% and 59% of children with their positive stringent and loose index models, 
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respectively. Clough and co-workers (59) from a prospective longitudinal study developed 
models to predict 12 months persistent wheezing in infant wheezers (three to 36 months of 
age) with at least one atopic parent. They have included in their models parameters such as 
personal atopy, parental atopy, number of siblings and immune markers measured in blood. 
Their best model had a maximum positive predictive value of 76% and a negative predictive
 
value of 68% in identifying a positive clinical outcome (child requiring prophylactic anti-
asthma treatment after one year). In the last mentioned study, the follow-up was only after 
one year duration. 
The knowledge of possible impact of severity of OAD in early life on later asthma is rather 
limited. Reijonen and colleagues from a  randomized controlled follow-up study (60) 
demonstrated increased risk of later asthma among hospital admitted young children with 
wheezing. Apart from this study, none of the studies included severity of frequency and 
persistence and /or hospital admissions for OAD in early life in their predictive models. 
5.6 Asthma and lung function in infancy through childhood 
Asthma may be associated with impairment of lung function as shown in many studies. The 
knowledge about lung function in childhood is increasing especially from prospective, 
longitudinal birth cohort studies (61-63). In the Tucson Children’s Respiratory Study (61;64), 
the chest compression technique to obtain partial maximum flow-volume curves together 
with assessments of the tidal breathing curve were studied in children between the ages of 1 
and 6 months before any recorded lower respiratory illnesses. The authors found that the 
children who had an lower respiratory illness during the first year of life had significantly 
lower mean values for several parameters (61). Moreover, when data for the first three years 
of life were assessed, the association became clearer, especially for parameters obtained from 
forced expiratory flow-volume loops (64). Follow-up data at six years of age have shown that 
the children who had wheezing before three years of age but not at the age of six (“transient 
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wheezers”) had diminished airway function (maximal expiratory flow at functional residual 
capacity [V’max FRC]) than those who did not wheeze during the first 3 years of life (12). 
Children who started wheezing in early life and continued to wheeze at the age of six 
(“persistent wheezers”) were more likely to have normal lung function in the first year of life, 
and diminished values for V’max FRC at six years of age (12). 
In the Manchester Asthma and Allergy Study birth cohort (62), 69 high risk infants (both 
parents atopic) underwent examination with the partial forced expiratory flow volume 
technique to determine V'max FRC. In this study, similar to findings from the Tucson study, 
authors found significantly lower V'max FRC in infants who had recurrent wheeze during the 
first year of life than in those who did not. In another birth cohort study from Perth (63), 
partial forced expiratory flow-volume curves obtained by rapid thoracic compression 
technique were assessed in 253 infants. In this study, the authors found that wheezing that 
begins or persists into the second year of life is usually associated with diminished lung 
function while wheezing during the first year of life is often a transient condition which 
improves with time (63). 
Carlsen et al (65) from the ECA birth cohort study assessed whether tidal flow patterns can 
be used to discriminate between children with asthma and those without respiratory illness 
and whether reversibility to salbutamol in young children can be detected by tidal breathing 
analysis. They found that the ratios of the time and volume until peak expiratory flow to the 
total expiratory time and volume, and the ratio of tidal expiratory flow at 25% remaining 
expiration to peak expiratory flow, were significantly lower in asthmatic children than in 
controls, and increased significantly after salbutamol inhalation in asthmatic children (65).  
 Based on the results from prospective longitudinal studies (53;61-63;65), there is substantial 
evidence to suggest that the changes in lung function in children with asthma and asthma-like 
symptoms occur as early as first year of life or may be present before the first respiratory 
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illness. It is also supported by our recent report (66) which has shown the association 
between reduced lung function at birth and increased risk of asthma at 10 years of age. 
5.7 Childhood asthma and bronchial hyper responsiveness  
Bronchial hyper responsiveness (BHR) is commonly seen in asthma and has a role in the 
pathophysiology of asthma (67). However, it can also be seen in asymptomatic subjects (68). 
It has been reported that BHR is already present in very young children (69).  
To investigate whether airway responsiveness is present from birth or if it develops as a 
result of subsequent insults to the respiratory tract, Young and colleagues (70) assessed 
airway responsiveness in 63 normal infants at a mean age of 4 1/2 weeks. Airway 
responsiveness was assessed by histamine inhalation challenge and the provocation 
concentration of histamine resulting in a 40% fall on V’max FRC from baseline (PC40) was 
determined. In this study, airway responsiveness was increased in infants with a family 
history of asthma, parental smoking, or both, as compared with the infants with no family 
history of asthma or smoking (70). From the Tucson Children’s Respiratory Study, Lombardi 
and colleagues (71) studied the relationship between BHR to dry, cold air at age six and the 
subsequent incidence of asthma. They found that BHR to cold air at age six was associated 
with an increased risk of developing subsequent asthma at age 11 after 5-year follow-up, but 
this effect was not independent of atopy and mild wheezing at age six (71).  
In a cross-sectional study of 2363 Australian school children (72), BHR was associated with 
atopic status, a history of asthma in either parent or a history of early respiratory illness. 
Furthermore, sensitization to house dust mite and cat was significantly associated with BHR 
in Chinese school children (73). 
The relationship between BHR and bronchodilator response is not well known. In a study of 
7-16 year old Dutch children bronchodilator response was weakly related to BHR (74). 
Lødrup Carlsen and colleagues (75) studied the bronchodilator response in young children in 
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subjects included in a nested case-control study (children with rBO) and controls without a 
history of lower respiratory disease by two years of age. They found that the mean per cent 
change in time to reach peak flow/total expiratory time (tPTEF/tE) from before to after 
salbutamol was significantly higher in children with rBO compared to controls. The latter 
study (75), however did not measure BHR in relation to bronchodilator response. 
5.8 Pathophysiology of asthmatic airways 
Asthma is an inflammatory disorder of the airways, which involves several inflammatory 
cells and multiple mediators that result in characteristic pathophysiological changes (76). 
There is evidence to suggest that asthma acts via a chronic inflammatory process that causes 
remodelling of the airways with increased thickening of reticular layer of basement 
membrane and smooth muscle hypertrophy (76;77). The inflammation with increased 
number of lymphocytes are uniformly distributed in the large and small airways in mild or 
severe asthma (78). The pattern of inflammation in the airways appears to be similar in all 
clinical forms of asthma, whether allergic or non-allergic (76). 
A study of bronchial biopsies in children aged 1.2-11.7 years by Pohunek and co-workers 
(79) found that eosinophilic inflammation and airway remodelling occur early in the natural 
history of bronchial asthma and are present even before asthma would be diagnosed based on 
clinical symptoms. However, Saglani and co-workers (80) working on endobronchial 
biopsies obtained from 53 infants (median age 12 months, range 3.4-26 months) during 
clinical bronchoscopy for severe wheeze and/or cough found no significant differences in 
reticular basement membrane thickness or eosinophilic inflammation in symptomatic
 
infants 
with reversible airflow obstruction, even in the presence of atopy. They found that the
 
reticular basement membrane thickness in all infants was significantly less thick than that
 
in 
the older children with asthma (80). 
The clinical spectrum of asthma is highly variable but the presence of airway inflammation 
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remains a consistent feature (76). Therefore, the importance of controller medications with an 
effect on the underlying inflammatory process has been emphasized in the most recent 
treatment recommendations (3;81).  
5.9 Asthma treatment in children 
The aim of present international and national treatment guidelines is to control asthma by 
reducing underlying lung inflammation, improving symptoms and prevent exacerbations 
(3;81-83). Advances in our knowledge of the exact mechanisms of asthma disease continue 
to lead to better management options. Anti-asthma medications may be classified as 
symptom-modifying (‘relievers’, e.g. bronchodilators) or symptom preventers (‘controllers’, 
e.g. inhaled cortiocsteroids) (14). Symptom-modifying drugs act by relaxing smooth muscle 
and thus improving airflow through the conducting airways (3). Symptom preventing drugs 
prevent or reduce symptoms of asthma, generally by their effect on the airway inflammatory 
process (3).  
A stepwise approach to pharmacological treatment to achieve and maintain control of asthma 
should take into account the safety of treatment, potential adverse effects, and the cost of 
treatment required to achieve control (3). For long term management of asthma in children, 
the standard classification of asthma severity from GINA (3) and the National Institutes of 
Health consensus guidelines (84) can be used. The guidelines for asthma management in 
adults differ from that of children and more so for younger children. Furthermore, the 
guidelines vary in different regions of the world based on local treatment traditions and 
documentation of effects. The specific medical treatment recommended to patients with 
asthma depends on the severity of their illness. In mild intermittent asthma (with symptoms 2 
days/week or less), no daily controller medication is needed, however relievers can be used 
when needed. In mild persistent asthma (symptoms more than 2 times/week, but less than 
one/day), low dose ICS can be used. For moderate persistent asthma (daily symptoms during 
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day and > 1 night/week), low-dose ICS plus long acting ß-2 agonist or medium or high dose 
ICS or low dose ICS plus leukotriene modifier can be used. For severe persistent asthma 
(continuous symptoms during day time and frequent night symptoms), high dose ICS as well 
as long acting ß-2 agonist and or leukotriene modifier can be added. These treatment 
strategies are some of the existing guidelines for asthma management and not necessarily 
practiced everywhere. In addition to anti-asthma medications, education programs for 
caregivers and self-management training for children with asthma is emphasized. 
As there is evidence supporting an apparent pathophysiologic relation between allergic 
rhinitis and asthma,  subjects with both rhinitis and asthma benefit by treatment with 
systemic agents, such as antihistamines alone or in combination with leukotriene modifiers, 
or corticosteroids (85). Immunotherapy can be used as an adjunct to standard drug therapy in 
allergic asthmatic children (86). 
5.10 Inhaled corticosteroids in childhood asthma 
According to the latest revision of GINA guidelines (3), inhaled corticosteroids (ICS) are 
preferred as first line treatment for persistent asthma in children. ICS were introduced more 
than three decades ago, and they still are regarded as the most effective therapy available for 
asthma. The extent of use of ICS depends on the prevalence of asthma and local practice of 
asthma management. Limited information has been available about how often ICS are used 
for treatment of asthma-like symptoms in early life. A cross-sectional telephone survey (87) 
was conducted during 1996-7 to parental caretakers of 2-12-year-old children who had been 
hospitalized with asthma. In this study of children with symptoms of moderate to severe 
persistent asthma (84), only 15% received ICS in contrast to guidelines recommendations 
(87). Recently, Bisgaard et al (88) reporting from a cross-sectional telephone survey of child 
population (n=9490) aged 1-5 years in the USA and Europe found that 5% children with 
wheezing illnesses have used ICS as regular treatment (varied from 4% in Northern Europe 
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to 7% in Southern Europe). 
In a large random sample (n=4,909) of Australian school children aged 8-11 years, 13 %  
reported use of ICS treatment during the period 1995-7 (89). In 1995-6 the use of ICS in the 
last 12 months was reported by 16 % of asthmatic German children (5-7 years and 9-11 
years-old) (90). More recently a fourfold increase (from 2.5% in 1988 to 11.3% in 2001) in 
ICS use in the last 12 months was reported among 12 year-old British child population (91).  
Effect on asthma symptoms, exacerbations, hyperresponsiveness 
The anti-inflammatory effects of ICS are well established; inhibition of the production of 
cytokines, direct effect on eosinophils and neutrophils and decreased vascular permeability 
causing reduction of mucosal oedema (92). There is consistent evidence that ICS treatment in 
asthma improves the control of asthma symptoms (93) and reduces hospital admissions 
(93;94). Efficacy has also been shown by stopping medication, as patients frequently 
experience an exacerbation of their asthma upon withdrawal of ICS, as shown both in 
preschool and school children (95;96). A recent meta analysis report of management of acute 
worsenings and exacerbations of asthma showed consistent evidence of beneficial role of ICS 
in children (97).  
ICS reduces BHR more effectively than other treatments (93). Koh et al (98) found 
significant improvement in
 
BHR in children receiving ICS and the extent of improvement in 
children was found
 
to be dependent on the degree of BHR in
 
their parents. Nielsen et al. (99) 
in a randomized controlled trial (RCT) have demonstrated that inhaled budesonide at a total 
dose of 800 microgram daily significantly improved symptoms, asthma exacerbation rates, 
and BHR as assessed by cold air challenge in asthmatic children aged two to five years. 
Teper et al (100) in a RCT have shown that fluticasone treatment daily in children with 
recurrent wheezing increased percentage of symptom-free days, decreased number of 
exacerbations, and decreased percentage of days on short-acting bronchodilator.  
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Effects of ICS on lung function in children 
In the last few years, the evidence is increasing regarding effects of ICS on lung function in 
preschool children (95;100;101). Teper and co-workers (100) in a double-blind placebo-
controlled randomised study assessed the effects of treatment with fluticasone in children 
younger than two years with recurrent wheezing. In the latter study, subjects were assessed at 
the
 
beginning and end of a 6-month treatment with fluticasone 125 µg two times daily or 
placebo. Lung function (V’max FRC) by the rapid thoracic-abdominal
 
compression technique 
has improved in the group treated with fluticasone compared to group treated with placebo 
(100). Nielsen et al (99) in a RCT studied 38 asthmatic children aged two to five years (mean 
age 53 months) involving a eight week of 400 microgram twice daily budesonide treatment. 
Lung function measured as the specific airway resistance using whole-body 
plethysmography; as resistance by the interrupter technique (Rint); and as resistance and 
reactance by the impulse oscillation technique showed significant improvement in the 
budesonide treated group compared to placebo (99).  
Several studies with different study designs have shown improved lung function in older 
children treated with ICS (94;102;103) whereas others did not (93). One non-randomized 
study (94) demonstrated that early treatment with inhaled budesonide after the diagnosis of 
asthma was established improved FEV1 in older children (mean age 6.2 years) both 
compared with the run-in period and with the control group. In patients not treated with 
budesonide an annual decrease in % predicted FEV1 of 1-3% was seen. After 3 years of 
treatment with budesonide, children who started therapy later than 5 years after the onset of 
asthma had significantly lower FEV1 than the children who received budesonide within the 
first 2 years after the onset of asthma (94). An uncontrolled retrospective study (102) 
demonstrated significantly lower spirometric values in children (mean age 6.5 years) treated 
with bronchodilators alone, compared to those receiving anti-inflammatory treatment with 
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ICS or disodium cromoglycate. In a Dutch randomized double-blind multicentre study (104),  
asthmatic children treated with inhaled budesonide showed increased FEV1 % predicted, 
post-bronchodilator FEV1 and increased peak expiratory flow rate when compared to 
placebo, which was then maintained for a median follow-up time of 22 months. Similarly, 
increase in FEV1 and improved BHR were seen in asthmatic children treated with inhaled 
budesonide in the study by Kerrebijn et al (105). Also Merkus et al (106) reported improved 
lung function (assessed as change of FEV1 and of maximal expiratory flows) after use of ICS 
in school children as compared to placebo. Pauwels and colleagues (107) have studied the 
benefits of early intervention with inhaled budesonide, starting less than two years after the 
diagnosis of asthma. This study which also included 1,974 were children aged 5-10 years and 
have received either budesonide or placebo once daily for 3 years in addition to their usual 
asthma medications. Subjects on budesonide had increased postbronchodilator FEV1 from 
baseline after 1 year and after 3 years as well as decreased risk of exacerbations and more 
symptom-free days than those receiving placebo (107).  
On the other hand, RCT from the Childhood Asthma Management Program (CAMP) (93) 
failed to show improvement on the degree of change in the FEV1 among 5-12 year old 
children treated with ICS for 4-6 years compared to placebo. In this study, 1041 children with 
mild to moderate asthma received either 200 microgram of budesonide twice daily or 
nedocromil or placebo (93). The enrolled subjects had asthma for a mean period of five years 
before they received treatment. However, the children given budesonide had lower airway 
responsiveness to methacholine and better control of asthma symptoms (93).  
A Dutch study (96) in school children treated for 28-36 months with ICS showed 
symptomatic improvement only during the treatment period while experiencing recurring 
asthma symptoms after stopping ICS. 
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Effect of early ICS treatment on prognosis of asthma 
Delayed introduction of ICS has been reported to result in reduced improvement in lung 
function compared with early use of inhaled steroids in childhood (94). Thus, a change in 
treatment strategy toward earlier introduction of ICS has been recommended. However, 
longitudinal studies in children are needed to clarify whether ICS has any effect on long term 
prognosis of asthma in children. 
During the last year, two RCTs (95;101) in preschool children were undertaken to assess if 
ICS treatment does alter the natural course of asthma in early childhood. However, these 
studies failed to show improved lung function after cessation of ICS treatment (95;101). In a 
double blind RCT by Guilbert and colleagues (95) studied whether treatment with fluticasone 
propionate can modify the subsequent development of asthma in preschool children (n=285) 
at high risk (positive asthma predictive index) for asthma. One group of children received 
two puffs of fluticasone (44 µg per puff) twice daily and the other group received placebo 
during the 24-month treatment period. Although there was initial improvement, there was no 
significant difference between the study groups
 
in any measure derived from impulse 
oscillometry at the end
 
of a third, treatment-free year (95). Authors concluded that two years 
of inhaled corticosteroid therapy did not change the development of asthma symptoms or 
lung function during a third, treatment-free year (95). Similar findings were observed in a 
double-blind RCT by Murray and co-workers (101). In this study, the effect of inhaled 
fluticasone propionate 100 microgram twice daily in young children (median age 1.2 years) 
who were followed prospectively and randomised after either one prolonged (>1 month) or 
two medically confirmed wheezy episodes. Children in the study had treatment for varying 
periods depending on symptom control (minimum 9 months, but could continue on treatment 
up to fifth birthday). Children were followed-up to five years of age, at which point children's 
lung function (specific airways resistance, forced expiratory volume in one second and 
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airway reactivity) was assessed. They found that the groups did not differ significantly with 
regards to current wheeze, physician-diagnosed asthma, lung function or airway reactivity 
(101). However, there was significant improvement in symptom scores and the number of 
unscheduled physician visits for children in the treatment group, but only during the third 
month of the study. 
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6 AIMS OF THE THESIS 
 
Main objective 
The main objective of the present thesis was to assess if early treatment with inhaled 
corticosteroids could modify disease progression in childhood.  
To study the main objective, it is of interest to know the prevalence of recurrent bronchial 
obstruction in early life and asthma in school age and assess how severity of the disease in 
early life can influence later occurrence of the disease. Secondly, the extent of use of inhaled 
corticosteroids in young children needs to be elucidated. Lastly, the purpose was to assess if 
ICS treatment has any effect on disease progression with relation to lung function by two 
years of age and occurrence of asthma by 10 years of age. 
Specific aims:  
1. To investigate the prevalence of recurrent bronchial obstruction and asthma in 
children in a general urban population.  
2. To determine how often inhaled corticosteroids were used for treatment of obstructive 
airways disease in childhood.   
3. To assess if ICS use had an effect on lung function in young children with recurrent 
bronchial obstruction. 
4. To define a severity score for severity of obstructive airways disease during the first 
two years of life and assess if the severity score can be used as a tool to predict 
asthma in school children. 
5. To explore if early ICS treatment in children with obstructive airways disease during 
the first two years of age can modify occurrence of current asthma in school children. 
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7 STUDY DESIGN 
Environment and Childhood Asthma study 
 
The ECA study was established in 1992 with main purpose of identifying factors including 
environmental factors that were involved in the development of asthma in young children, as 
a collaborative study between Department of Paediatrics at Ullevål University Hospital and 
Section for Epidemiology at National Institute of Public Health.  
The ECA study is a prospective birth cohort with 3,754 children enrolled at birth in Oslo 
during 15 months from January 1
st
1992. See figure 1 below on the study design and main 
methods of clinical part of the ECA study. 
 
Inclusion criteria were:  
• Babies born at Ullevål Hospital and Aker Hospital, Oslo. 
• Birth weight of more than 2000 g. 
BIRTH 0-2 YEARS 10 YEARS 
 
Recruited 
n=3754 
 
 
 
 
Case control 
study 
n=516/612 
(84.3%) 
Follow-up 
 
n=1019/1215 
(84%) 
 
Lung function 
n=803 
 
Questionnaires every 6 
months from birth to 2 
years 
Parental interviews 
Clinical visit  
Lung function tests 
Skin prick tests (at 2  
years only) 
Parental interviews 
Clinical visit 
Lung function tests 
BHR tests 
Skin prick tests 
 
Study design and main methods of the ECA birth cohort study. 
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• Absence of any illness likely to impair respiration (severe respiratory, cardiovascular, 
neuromuscular or metabolic disease).  
• No requirement for assisted ventilation or oxygen therapy beyond six hours after 
birth.  
Exclusion criteria were:  
• Plans to move out of Oslo within six months. 
• Insufficient language comprehension by the parents to be able to complete 
questionnaires.  
Lung function measurements (tidal flow-volume loops and passive respiratory mechanics) 
were performed shortly after birth in 803 healthy newborn children (108). 
Nested case control study  
A nested case-control study was established during the first two years of life to perform 
detailed examinations of children with recurrent bronchial obstruction (rBO) (n=306) and 
age-matched controls (n=306). Case was defined as a child with recurrent (more than one) or 
persistent (more than four weeks) doctor confirmed bronchial obstruction (BO) by two years 
of age. Control was defined as a child without symptoms of lower respiratory illness born 
closest in time to the case. 
The following recruitment procedures were performed to identify possible children with rBO 
(cases) for the nested case-control study: 
• All questionnaires and parental interview forms were scrutinized for 
possible symptoms of recurrent BO.  
• Clinical signs related to BO were recorded on a check-box card by all 
doctors examining a participating child during a respiratory tract illness, 
and the cards were returned to the study personnel at least every 6 months 
for identification of a possible case.  
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• All family doctors, well baby clinics, accident and emergency departments 
and paediatric hospital wards were requested to refer participating children 
with possible or established BO to the study paediatrician.  
Any of the above events led to a request to attend a clinical examination by the study 
paediatrician for eligibility to enrol into the nested case-control study. All children were 
asked to attend one or two visits (if older or younger than 20 months, respectively, at 
enrolment in the case-control study). The first clinical visit was performed as soon as 
possible after eligibility was established at a mean age of 11 months, and the second clinical 
visit at a mean age of 25 months. The attendance rate at the two-year visit was 84 %, almost 
equally distributed between cases (n = 265) and controls (n = 251). 
The nested case control study was performed in the absence of clinical signs of bronchial 
obstruction or upper respiratory infection, and consisted of a structured interview (detailed 
medical and allergic family history, pet keeping and tobacco smoke exposure), clinical 
examination, lung function assessed by tidal flow volume loops including ßeta-2 
responsiveness, skin prick test to food and common inhalant allergens, serum for markers of 
inflammation, immunoglobulins (Ig), and total IgE, as well as environmental exposure 
assessments (indoor and outdoor). 
10 year follow-up study 
To understand better the early risk factors for later asthma and allergy development in school 
children, a follow-up study of children with lung function measured at birth (n = 803) and/or 
a clinical investigation by 2 years of age, was initiated in 2001 (see figure 1 above).  
A total of 1215 children aged 9-10 years were invited. Of these, 1019 (84 %) attended the 
two-day follow-up study between September 2001 and July 2004. The study included 
detailed parental structured interview, blood tests, skin prick tests (SPT), spirometry, 
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methacholine challenge test and clinical examinations on day 1, and an exercise test by 
treadmill running within 1 week.  
Other clinical examinations included exhaled nitric oxide measurements, urine sampling, 
markers of airway inflammation, genetic analyses, and environmental exposure tests, which 
are not reported in the studies included in the present thesis. 
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8 METHODS 
8.1 Parental questionnaires  
All children were followed from birth until their second birthday half-yearly with 
questionnaires completed by the parents/guardians, for the first time at the maternity ward. 
Questionnaires included information on the child’s health with specific questions related to 
respiratory, allergic, skin as well as general diseases and details about medical treatment 
including ICS, family history of atopic or other diseases, and parental smoking habits. 
Questions also included infectious diseases, socio-economic factors and environmental 
exposures. Of 3754 enrolled children, 3697 subjects also had a completed two year follow-up 
questionnaire. 
8.2 Parental interviews  
At inclusion and 2 years 
Furthermore, both at the first clinical visit at debut of OAD (mean age 11 months, range 3-21 
months) and at the two year clinical visit (mean age 26.8 months, range 2-41 months), a 
parental structured interview by the study doctor was completed regarding diseases of index 
child and primary family members, infections, environmental exposures, housing, socio-
economic factors and any type of medical treatment.  
The following questions regarding treatment of rBO until two years of age were asked: “the 
use of preventive or regular therapy for wheezing?”, if yes, “the use of ICS as regular 
therapy?” if yes, questions regarding age at start, duration and age at cessation of ICS therapy 
were asked. 
The information regarding severity of obstructive airway symptoms until two years of age 
was assessed by the following questions: “has the child ever had wheezing and/or shortness 
of birth?”, if yes, “the number of episodes with wheezing” and/or “the number of months 
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with persistent wheezing” and “was the child ever admitted to hospital due to wheezing?” 
and if yes, “the number of hospital admissions for wheezing”. Answers to these questions 
were the basis of calculating severity score of OAD by two years of age (see the section on 
severity score). 
At 10 years 
Parental interviews were conducted by study physicians where parents of the enrolled 
children answered a structured, extensive questionnaire regarding housing, socio-economic 
factors, infections, diseases of index child and primary family members. The central core 
questions from International Study of Asthma and Allergies in Children (ISAAC) validated 
in Norwegian (109) were asked specially in relation to airways symptoms, medical treatment, 
tobacco exposure, physical activity and diet.  
For defining asthma ever (history of asthma) at 10 years of age, the following questions were 
asked:  
“Has your child experienced dyspnoea, chest tightness and/or wheezing during the age 
periods 0-3 years and/or 4-10 years?”  
“Has the child been diagnosed having asthma by a doctor?” if “yes”, “age at onset”. 
“Has the child ever taken medicine for asthma 0-3 years and/or 4-10 years??” if “yes”, “what 
type of medicine” and “age at start of therapy”. 
As a part of defining current asthma at 10 years of age, the following questions were asked:  
“Has your child experienced dyspnoea, chest tightness and/or wheezing during the last 12 
months?”  
 “Has the child taken medicine for asthma during the last 12 months?” if “yes”, “what type of 
medicine”. 
8.3 Lung function measurements 
From birth to two years of age 
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Lung function was measured in 803 children shortly after birth (108) at a mean age 2.7 days 
by tidal flow volume (TFV) loops (n=802) and respiratory mechanics by the passive 
occlusion technique (n=664). All children were healthy at the time of lung function 
measurements. 
Lung function was measured in 106 children included in the nested case-control study shortly 
after presentation of OAD at a mean age of 11 months. Lung function was also measured at 
the two year clinical visit in 312 children (264 with rBO and 148 controls) participating in 
the nested case control study. 
Measurements of TFV loops using SensorMedics 2600 system (Anaheim, California) were 
performed by trained investigators and attempted in all subjects awake and quietly breathing 
(108;110). Among rBO children who were using medications, short-acting bronchodilators 
were withheld on the morning prior to testing (none of the children had received long-acting 
bronchodilators). TFV loops were obtained with a face mask (Vital Signs inc.) connected to 
pneumotachograph (4500 series, Hans Rudolph, Missouri, USA) with a flow range of 0-30 
l/min. Dead-space of the system was 2.4 ml, and of the face mask was 8.4-11 ml. Volume 
was derived by the digital integration of the flow signal, which occurred at a sampling 
frequency of 256 samples per second without any filtering of the raw signal. Calibration of 
the flow and volume signals was performed daily, using a 100 ml precision syringe (Hans 
Rudolph). 
Four representative TFV loops were stored for the final analysis. Each loop was chosen from 
eight stored loops obtained from series of breaths during established tidal breathing. The 
loops were selected from tidal breaths with as stable volume and shape of the loops as 
possible, and the respiratory rate being as low as possible. The ratio of time until peak tidal 
expiratory flow to total expiratory time (tPTEF/tE ) was calculated by separate measurements 
of the time to peak tidal expiratory flow and total expiratory time by the software programme 
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of the computer (108;111).  
The shapes of TFV loops represented by tPTEF/tE are reported to reflect OAD in children 
(111-115), as well as predict wheeze in children under three years of age (115). Based on this 
information, in paper II, we have used tPTEF/tE to assess possible effects of ICS treatment on 
evolution of lung function in children with rBO. 
Bronchodilator responsiveness  
Bronchodilator responsiveness was assessed by TFV measurement immediately before and 
15 minutes after inhaled, nebulized salbutamol 0.05 mg/kg bodyweight (111). The subjects 
were classified as responders to salbutamol when the increase in mean tPTEF/tE after inhalation 
of salbutamol exceeded 2 SD of the intrasubject variation. Non-responders had a difference 
in mean tPTEF/tE before to after salbutamol inhalation of less than two SD of the initial 
intrasubject variation. 
At 10 years 
Maximum forced expiratory flow volume loops were measured according to European 
standard (116) (reference values of Zapletal (117)) on a SensorMedics Vmax 20c 
(SensorMedics Diagnostics, Yorba Linda, CA, USA) on four occasions; prior to metacholine 
and exercise challenge tests and after salbutamol given at the end of challenge tests, 
respectively (on separate days). Lung function measures were forced expiratory volume in 
one second (FEV1) % predicted, forced expiratory flow at 50 % of vital capacity (FEF50) % 
predicted and forced vital capacity (FVC) % predicted. The reported values in paper I were 
the best baseline values obtained before challenge testing. 
8.4 Bronchial hyper responsiveness tests 
BHR tests were performed at 10 year follow-up visit. Methacholine challenge test was 
performed the first day and exercise challenge (treadmill run) within one week after 
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withholding short and long acting ß-2 agonists for at least 12 and 48 hours respectively, and 
leukotriene antagonists for 72 hours.  
Methacholine provocation test 
BHR by methacholine provocation was measured according to international guidelines (118) 
by inhalation of doubling doses of methacholine, nebulised by the Spira nebuliser (Spira 
Respiratory Care Center Ltd, Håmeenlinna, Finland), until reaching a cumulated dose of 
methacholine causing a reduction in forced expiratory volume in 1 second (FEV1) of 20 % 
(PD20) methacholine) or reaching the maximum cumulated dose (PD20) of 22.4 µmol 
methacholine. 
Exercise provocation (treadmill run) test 
A standardized exercise test (119) was performed by a 6-8 minute treadmill run, of which the 
last four minutes at  95 % maximal heart rate with 5.5 % inclination, with a 20 minute 
observation time after running. FEV1 was measured before, and three, six, ten and 15 minutes 
after running as well as 10 minutes after inhalation of nebulised salbutamol (0.1 ml per 10 kg 
bodyweight) administered 20 minutes after running. The exercise challenge test was 
considered positive with ≥10 % reduction of baseline FEV1 3-20 minutes after running 
ceased. 
8.5 Skin Prick Tests 
At 2 years 
Skin Prick tests (SPT) were performed in 498 children at the two year visit, according to 
Nordic standard (120). The following standardised extracts from ALK (Hørsholm, Denmark) 
were used: egg white, cows milk, dermatophagoides (D.) pteronyssinus, timothy grass, cat 
dander, dog dander, silver birch, mugwort and cladosporium herbarum, as well as saline 
negative control and histamine control (10 mg/ml). Sensitization was regarded as positive 
with a wheal for the allergen in question of at least half the size of the wheal for the 
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histamine positive control. 
At 10 years 
SPT to common inhalant and food allergens were performed in 1010 children attending 10 
year follow-up visit with Soluprick® allergens (ALK Albello, Denmark). Sensitization was 
considered positive with a wheal diameter ≥ 3mm larger than the negative control (NaCl). 
The following allergens were used: domestic mites (Dermatophagoides (D.) pteronnysinus 
and D. farinae), German cockroach, dog, cat, and rabbit dander, birch, timothy (grass) and 
mugwort pollens, moulds (Cladosporium herbarium and Alternaria alternata), egg white, 
milk, peanut and codfish.  
8.6 Severity score  
As reported in paper III, a severity score for each individual subject was calculated based 
upon the clinical criteria present during 0-2 years of age: number of episodes of bronchial 
obstruction, number of months with persistent bronchial obstruction and number of hospital 
admissions due to bronchial obstruction (see figure below).  
 
 
 
Figure 2 (figure 2 from paper III): Criteria used to define severity score. Reprinted with the 
permission from BMJ Publishing group Ltd, United Kongdom. 
 
The information was obtained from questionnaires completed by the parents every six 
months and parental interview forms at debut visit and at the two year visit. Severity of OAD 
by two years of age was assessed by the questions previously described in the section about 
parental interviews.  
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Minimum and maximum score for an individual was 0 and 12, respectively. Two no-BO 
subjects had severity score of one. 
The severity score was also calculated for the subjects at the age of 12 months, based on 
questionnaire data obtained every six months from birth to one year of age. The score at 12 
months was constructed from data obtained in questionnaires only, with less detailed 
information than that obtained during parental interviews at the two year visit.   
8.7 Statistical methods 
General considerations 
The outcomes were compared between the groups and differences were assessed for 
statistical significance, provided normal distribution of the data in question, between 
unpaired groups by using the unpaired (two-sample) t-test, and comparisons between paired 
groups with paired (one-sample) t-test. If data did not satisfy normal distribution, the non-
parametric Mann-Whitney or Wilcoxon signed rank test were used, respectively. Analysis of 
variance tests were used for comparing multiple groups. Correlation analyses were performed 
with Pearson’s correlation, using Fishers Z-transformation to obtain two-tailed test for 
significance. Lung function values were given as mean values with 95 % confidence intervals 
(CI).  
Receiver operated characteristic analysis 
Receiver operating characteristic (ROC) curves are used to assess the accuracy of a 
diagnostic test (121). The technique is used when one has a criterion variable which will be 
used to make a yes or no decision based on the value of this variable. The ROC curve is a 
graphical approach to plot the sensitivity versus 1-specificity for each possible cut-off, and to 
join the points (121). In paper III, ROC curve analysis was done by using the severity score 
1-12 at two years as a continuous variable and classification by current asthma at ten years of 
age as clinical outcome. Sensitivity (%), specificity (%), positive predictive value (PPV) (%) 
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and negative predictive values (NPV) (%) was calculated for each value of the severity score 
(1-12) and reported in table 4 of paper III.  
Logistic regression 
The risk of current asthma at the age of 10 years was assessed using logistic regression 
analysis comparing rBO children with severity score of above five and no BO subjects (paper 
III). Odds ratios (OR) including 95% CI were calculated after adjustment for gender, parental 
atopy and atopic eczema by two years of age as well as allergic skin sensitization at two year 
visit. The appropriateness of the logistic model was assessed using Hosmer and Lemeshow 
Goodness of fit statistic for the overall fit of the model and Dfbetas and Cbar statistics to 
assess the influence of the single subjects (122). Linearity of severity score as a continuous 
variable was assessed using Hosmer’s procedure (122).  
The prediction models of loose and stringent indices suggested by Castro-Rodriguez et al 
(58) were approximated to similar data in paper III. The data that was used in the paper by 
Castro-Rodriguez et al (58) regarding frequency of wheezing the first three years of life, 
history of eczema, parental history of asthma, eosinophilia, and wheezing without colds was 
also found in our questionnaires and parental interviews between 0-2 years of age. However, 
we did not have comparable data regarding allergic rhinitis between 0-2 years of age (that is 
in our view difficult to assess in this age group) in our study and therefore data used to 
calculate asthma indices suggested by Castro-Rodriguez et al (58) was approximated. 
Sensitivity, specificity, positive and negative predictive values for both loose and stringent 
indices were calculated and presented in table 4 of paper III. 
Propensity modelling and propensity score 
Logistic regression by propensity modelling was used in paper IV to assess the risk of current 
asthma among rBO children with and without early ICS treatment compared to no-BO 
children. The propensity score has been proposed as a method of adjusting for bias in 
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treatment assignment present in observational studies (123) and as such being recommended 
in a paper from the Food and Drug Administration in the USA to correct for non-randomness 
(124). Since several factors that were expected to be associated with the use of ICS by two 
years could also be expected to affect later prognosis of the disease, a propensity model (125) 
was developed to adjust for such factors. A common approach is to include various 
predictors of outcome. The propensity model included gender, severity score by two years, 
and atopic dermatitis by two years as covariates. Furthermore, parental atopy and allergic 
skin sensitization by two years of age were assessed as possible confounders; however, they 
were not included in the propensity model due to questionable model fit. The propensity 
method used in paper IV is a logistic regression analysis with the use of ICS, as the 
dependent variable. The propensity scores are the predicted probabilities for using ICS for 
each individual. To assess the characteristics of the propensity scores, mean values were 
calculated for two different groups (ICS-treated and ICS-naïve children) of subjects. In the 
final logistic regression analysis the propensity score was used as a covariate together with 
the use of ICS treatment.  
Regression to the mean 
The potential risk of regression to the mean as described by Altman (126) was assessed in 
paper II in different treatment groups (ICS-treated, ICS-nontreated and controls). The 
solution to this problem as described by Altman (126) is to take the average of initial (X) and 
final measurement (Y) and calculate the correlation between this quantity and the observed 
change: (X + Y)/2 with X–Y.  
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9 STUDY SUBJECTS  
Aim 1 
“Investigate the prevalence of recurrent bronchial obstruction and asthma in children in a 
general urban population”. 
For the purpose of investigating the extent of prevalence of rBO by two years of age, the 
study included all children from the entire cohort who had completed all four follow-up 
questionnaires (3697 of 3754 subjects) as well as all children defined with rBO who had 
attended at least one visit. 
To assess the prevalence of asthma until 10 years of age, the study included the 616 of 803 
children with lung function measurements shortly after birth who attended the 10 year 
examination at a mean age (standard deviation) of 10.9 (0.9) years. Sufficient information 
was available to classify 614 children as having a history of asthma or not and 606 as having 
current asthma or not. The included children were representative of the entire birth cohort 
(n=3754) as there were no significant differences at birth with respect to gender, parental age, 
parental asthma, eczema or rhinoconjunctivitis, maternal smoking during pregnancy, pet 
keeping, parental education, paternal employment rate, family income or number of siblings 
(table 1, paper I).  
Aim 2 
“Determine how often inhaled corticosteroids were used for treatment of obstructive airways 
disease in early childhood.” 
The study included all children from the entire cohort who had completed all five 
questionnaires (3697 of 3754 subjects) up to two years of age as well as all children defined 
with rBO who had attended at least one visit.  
Aim 3  
“Assess if ICS treatment had an effect on lung function in young children with rBO.” 
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For this aim, the 69 children from the case control study (54 cases and 15 controls) up to two 
years of age in whom lung function measurements had been obtained on two occasions were 
investigated. ICS had been used by 21 (ICS+) of the 54 cases (39%) and none of the controls. 
All children were steroid naïve at the first study visit and 79% remained so until two years of 
age (ICS-). Mean (SD) duration of treatment with ICS was 10.3 (6.5) months.  
Of all the children participating in the case control study (n =516), 59 rBO children received 
ICS during the first two years of life, and 32 of these were still using ICS at the two year 
visit. None of the control children used ICS during the first two years of life. 
A group of children used only for assessing the representativity of the included children (54 
cases and 15 controls), comprised of remaining 243 children (110 with rBO and 133 
controls) who had lung function measurements obtained at visit 2 only and the remaining 37 
children (19 with rBO and 18 controls) with lung function measurements obtained at visit 1 
only. The 69 included children did not differ significantly from the remaining non-included 
children with respect to demographic data (sex, weight, height, positive SPT, daily maternal 
smoking or parental atopic disease) whereas age was significantly lower (p=0.004) among 
the included children.  
Aim 4 
“Define a severity score of OAD in the first two years of life and assess the usefulness in 
predicting asthma in school children.” 
To define a severity score, we gathered information from subjects having recurrent bronchial 
obstruction (also defined as ‘case’ by two years of age) and compared with those subjects 
without BO (also defined as ‘control’ by two years of age). The study focused on clinical 
presentation at the time of investigation (two and 10 years) to assess if severity score by two 
years can predict asthma at 10 years of age. For this purpose, the subjects from the nested 
case control study who attended both the two year and 10 year visits (follow-up rate of 89%) 
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comprising 239 rBO subjects and 220 no-BO subjects, were investigated (see figure below). 
Mean age (SD) at the 10 year visit was 10.3 (0.7) years. However, due to insufficient data at 
two and/or 10 years in 10 children, the present study included the 449 children (233 rBO 
subjects and 216 no-BO subjects) with complete data to calculate severity score at two years 
of age and current asthma at 10 years of age. 
 
 
Figure 3 (Figure 1 from paper III). Flow chart of the study subjects. *Children with rBO 
were defined as children with recurrent bronchial obstruction by two years of age. Control** 
(rBO-): children were: age-matched children without bronchial obstruction by two years of 
age. Reprinted with the permission from BMJ Publishing group Ltd, United Kongdom.  
 
Aim 5 
“Explore if early ICS treatment in children with obstructive airways disease in the first two 
years of life can modify occurrence of current asthma in school children.” 
Similar to the study in paper III, we gathered information from subjects having obstructive 
airway symptoms and compared with those subjects without obstructive airway symptoms by 
two years of age. Additionally, the information on ICS treatment by two years of age in the 
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subjects was sought. As in paper III, the subjects from the nested case control study who 
attended both the two year and 10 year visits comprising 239 rBO subjects and 220 no-BO 
subjects were assessed. Of those, 452 had sufficient data to assess current asthma at 10 years 
of age. Mean age (SD) at the 10 year visit was 10.3 (0.7) years. Fifty one (21.9 %) rBO 
children reported use of ICS between 0-2 years of age, whereas the remaining 182 rBO 
children and none of the control subjects received ICS during these years. Mean (SD) 
duration of ICS therapy until two years was 8.5 (5.9) months (range 1-22 months).  
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10  OUTCOMES 
 
For the aim of investigating the prevalence of asthma and current asthma at 10 years 
of age following outcomes were used (paper I): 
Asthma was defined by at least two of the following three criteria being fulfilled:  
1. Dyspnoea, chest tightness and/or wheezing 0-3 years and/or 4-10 years. 
2. Physician’s diagnosis of asthma. 
3. Use of asthma medication (ß-2 agonist, sodium cromoglycate, corticosteroids,  
leukotriene antagonists and/or aminophylline) 0-3 years and/or 4-10 years. 
Current asthma was defined as asthma (by definition above) plus at least one of the 
following: 
1. Dyspnoea, chest tightness and/or wheezing during the last 12 months. 
2. Use of asthma medication (ß-2 agonist, sodium cromoglycate, corticosteroids, 
leukotriene antagonists and/or aminophylline) during the last 12 months. 
3. Positive exercise test. 
Wheeze ever was defined by a positive response to the questions “Has your child 
experienced dyspnoea, chest tightness and/or wheezing during the age periods 0-3 years 
and/or 4-10 years?” 
Lung function outcomes: baseline (pre-bronchodilaltor) FEV1 % predicted and FEF50 
% predicted. 
 
For the aim of assessing the extent of use of ICS treatment in young children by two 
years of age, the outcome was subjects who received ICS treatment during the first 
two years of life (paper II). To assess if ICS treatment had an effect on lung function 
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in young children with rBO, the main outcome measure was tPTEF/tE ratios derived 
from TFV loops measured at debut visit (visit 1) and visit 2 (two year visit). Baseline 
tPTEF/tE  (pre-bronchodilator) and post-bronchodilator tPTEF/tE ratios were calculated at 
both visits (paper II).  
The secondary outcome was bronchodilator responsiveness expressed as change in 
tPTEF/tE from before to after salbutamol inhalation given by the formula: (tPTEF/tE after 
salbutamol – baseline tPTEF/tE) x baseline tPTEF/tE 
-
1, calculated at both visits (paper 
II). 
For the aim of defining a severity score of obstructive airways disease in the first two 
years of life and assess if the severity score can be used as a tool to predict asthma in 
school children following outcomes were used: the primary outcome was current 
asthma at 10 years of age and the secondary outcome was non-specific BHR to 
methacholine (PD20) (paper III).  
For the aim of exploring if early ICS treatment in children with obstructive airways disease at 
two years of age can modify occurrence of current asthma in school children, the main 
outcome was current asthma at 10 years of age (paper IV). 
 
Definitions:  
 
Allergic skin sensitization  
Allergic skin sensitization reported in papers I, II, III and IV were considered 
positive with ≥ one positive skin prick test to common inhalant and/or food allergens.  
Parental atopy 
Parental atopy reported in papers II, III and IV was defined as asthma and/or 
rhinoconjunctivitis reported in at least one parent by two years of age.
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11  ETHICAL CONSIDERATIONS 
 
Parents of all eligible children received written information at each phase of the 
study. Signed, informed consent was obtained from parents of all subjects upon 
enrolment. The study was approved by the Regional Committee for Medical 
Ethics and the Norwegian Data Inspectorate. Applications for renewed approval 
were obtained for the 10 year follow up study. The study was registered in the 
Norwegian Biobank Registry, Ullevål University Hospital in Oslo. 
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12 MAIN RESULTS OF THE PRESENT STUDIES 
12.1 Prevalence of recurrent bronchial obstruction or asthma and allergic sensitization 
in childhood 
Recurrent bronchial obstruction in 0-2 year old children 
Of all healthy children enrolled at birth in the study (3697 of 3754 with complete 
questionnaire data by two years of age), 306 subjects had documented symptoms of recurrent 
bronchial obstruction by two years of age, corresponding to prevalence of 8.3 % with rBO in 
young children (paper III). 
Asthma until 10 years of age 
At the 10 year follow-up visit, lifetime prevalence of asthma was 20.2 %, current asthma 
11.1 %, doctors’ diagnosis of asthma 16.1 %, and 30.6 % of the school children suffered 
from wheeze ever (paper I). Boys had more often than girls current asthma (14.4 vs. 7.1 %, 
respectively, p=0.008) and wheeze ever (36.9 % vs. 22.5 %, respectively, p=0.002). Wheeze 
was reported by 8.8% of subjects during the first three years of age only, compared to 9.2 % 
during 4-10 years of age only. Of 21.4 % children who wheezed during the first three years 
of age, 41.2% reported no later wheeze (paper I). 
Lung function in asthmatic children at 10 years 
At the 10 years follow-up visit, lung function as FEV1 % predicted (mean, 95% CI) was 
significantly reduced among children with current asthma (95.8, 93.3-98.3) compared to 
asthma without current symptoms (100.3, 97.7-102.8) and no asthma (99.1, 98.3-100.0) (p = 
0.021). The corresponding values for FEF50 % predicted were 79.0, 73.8-84.0 for current 
asthma, 86.7, 82.1-92.1 for asthma without current symptoms and  91.0, 89.4-92.7 for 
subjects without asthma, respectively, (p<0.001 for trend).  
Allergic skin sensitization in asthmatic children at 10 years  
At the 10 year visit, positive SPT to at least one allergen was found among 29.3% of all 
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children, significantly more frequent among children with current asthma (56.1%) compared 
to asthmatic children without current symptoms (26.8%) and no asthma (26.0%) (p<0.001). 
Children who wheezed during 4-10 years of age were more often sensitized than children 
who had never wheezed or wheezed only during the first three years of age. Boys more often 
than girls were sensitized to at least one allergen (36.2% vs 26.1%) (p<0.001) (paper I). 
Parental atopy in asthmatic children at 10 years 
A parental history of asthma and/or rhinoconjunctivitis by 10 years of age was significantly 
more common among children with current asthma (67.2%) compared to asthmatic children 
without current symptoms (49.1%) and children without asthma (49.6%) (p=0.024). The 
effect was mainly due to parental asthma (29.9% in children with current asthma, 12.3% in 
children with previous asthma and 13.5 % with no asthma, p=0.002) (paper I). 
12.2 Extent of use of inhaled corticosteroids in young children 
From the entire cohort (3697 of 3754 with complete questionnaire data by two years of age), 
77 children corresponding to a prevalence of 2.1 % and 64 of the 306 children (20.9 %) with 
rBO (20.9%) had received treatment with inhaled steroids by the age of two years (paper II). 
Mean (SD) duration of ICS treatment among the rBO children with repeated lung function 
measurements (n=21) was 10.3 (6.5) months up to the two year follow-up visit (paper II).   
12.3 Effect of inhaled corticosteroids on lung function in young children 
Visit 1 
Baseline (prebronchodilator) tPTEF/tE was significantly lower among children with rBO 
compared to controls at the inclusion visit (table 2, paper II). Furthermore, the mean (95% 
CI) baseline tPTEF/tE at the first visit was significantly lower in rBO children who later 
received ICS compared to those who did not (0.17, 0.15-0.20) versus 0.23, 0.19-0.28)) 
(p=0.03). Analysis of baseline tPTEF/tE between all the children who had received ICS before 
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two years of age with lung function measurements (n=39) compared to the corresponding 
rBO children who had never received ICS (n=125) confirmed the statistically significant 
differences with a mean difference in tPTEF/tE in favour of the ICS-naive children (0.07 0.03-
0.12) (p=0.003).  
Visit 2 
Baseline tPTEF/tE  (prebronchodilator) was also significantly lower among children with rBO 
compared to controls (table 2, paper II) whereas it was not significantly different between the 
treatment groups (ICS-treated and steroid-naive) at two years of age. At visit 2, baseline 
tPTEF/tE did not differ significantly between all the children who had received ICS by two 
years with lung function measurements (n=39) compared to the corresponding children who 
had never received ICS (n=125) (p=0.2)). 
Baseline lung function did not differ significantly among the included 69 children as 
compared to the children with lung function measurements on one occasion only, neither at 
visit 1 (0.24, 0.21-0.27 versus 0.25, 0.21-0.29, respectively) nor at visit 2 (0.27, 0.25-0.30 
versus 0.28, 0.27-0.29, respectively).  
Change in lung function from visit 1 to visit 2 
The mean difference in baseline tPTEF/tE from first to second visit was significantly higher 
(borderline) in the ICS-treated group only (0.057, -0.003-0.116) (p=0.06) (figure 4) and 
correlated significantly with duration of ICS treatment (r=0.481, p=0.027). 
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Fig. 4 (figure 2 from paper II).—Baseline lung function in 54 children with recurrent 
bronchial obstruction and controls ( ) at enrolment in case-control study and at 2 yrs (visit 1 
and 2, respectively). Lung function represented by the ratio of time to peak expiratory flow to 
total expiratory time (tPTEF/tE) was significantly lower among children who later received 
inhaled corticosteroids (ICS; ICS+: ) compared to those who did not receive ICS (ICS–: •) 
at first visit (p=0.03), but not at second visit (p=0.12). 
Reprinted with the permission from European Respiratory Society Journals Ltd, 
UK. 
 
Bronchodilator responsiveness 
In children with rBO, bronchodilator responsiveness was significantly higher (p=0.02) as 
compared to controls at visit 1 but not at visit 2, but without statistically significant 
differences between ICS+ and ICS- children at either visit. However, postbronchodilator 
tPTEF/tE  ratios were not significantly different between the ICS+, ICS- and control groups 
either at visit 1 or visit 2. 
12.4 Impact of severity of obstructive airways disease by two years of age on asthma at 
10 years of age 
Severity score by two years of age 
The mean (95 % CI) severity score of all rBO subjects at two years of age was 4.6 (4.2-5.0), 
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significantly higher among rBO children who developed current asthma, 5.5 (4.9-6.1) 
compared to rBO children without current asthma 4.0 (3.6-4.5) (p<0.001). The mean severity 
score at the age of 12 months among rBO+ subjects was 1.04 (0.81-1.27).  
 
Figure 5 (figure 3 from Paper III). The severity score distribution at two years of age. 
Reprinted with the permission from BMJ Publishing group Ltd, United Kongdom. 
 
Based upon the analysis of all included 449 children in the study reported in paper III, a 
linear association was found for severity score at two years of age as a predictor for current 
asthma at 10 years of age; the ORs (95% confidence intervals) for a one-point increase in 
severity score was 1.35 (1.25-1.45) and for a two-point increase in severity score 1.82 (1.57-
2.11) respectively. By using the severity score calculated at the age 12 months the OR for 
current asthma at 10 years was 1.30 (1.11-1.52) for a one point increase in severity score. 
Receiver operated characteristic analysis 
The ROC analysis for severity score at two years as a continuous variable classified by 
current asthma at ten years, revealed an area under the curve of 0.78 (95% C.I.: 0.73, 0.83, 
p<0.0001) (see figure below). In the analysis, the cut-off value six provided the best value to 
predict current asthma at 10 years of age (odds ratio 7.9 %, sensitivity 51.5 %, specificity 
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88.1 %, PPV 54.3 % and NPV 86.8 %) (table 4, paper III). 
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Figure 6. Severity score at two years of age and the ROC curve of current asthma at 10 years 
of age. 
  
 
Adjusted OR and the results of the ROC analysis are shown in table 4 of paper III for each 
level of severity score with sensitivity, specificity, positive and negative predictive values for 
current asthma. 
Severity score at 12 months of age 
The ROC analysis for severity score at 12 months, classified by current asthma at 10 years 
revealed an area under the curve of 0.59 (0.54-0.64) (p=0.007). However, with a cut off value 
of severity score at 12 months set to two (identified as the best value), the sensitivity was 
only 16.8% (9.9%-25.9%), the specificity 94.3% (91.3%-96.5%) with a positive predictive 
value of 44.4% and negative predictive value of 80.6%.  
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Current asthma at 10 years of age 
Current asthma at 10 years was significantly more frequent among rBO children (36.5 %) 
compared to no-BO subjects (5.6 %) (p<0.001).  More boys than girls had current asthma at 
ten years of age (p=0.05). The rBO children with current asthma at 10 years of age were 
more often hospitalised due to BO by two years of age (p=0.01) than no-BO children without 
current asthma at 10 years of age (table 3 paper III).  
Risk of current asthma at 10 years of age 
The adjusted OR (adjusted for gender, parental atopy and atopic eczema by two years of age 
as well as allergic skin sensitization at two year visit) for current asthma among all rBO 
children compared to no-BO children was 7.9 (4.1-15.3). Compared to no-BO children, the 
adjusted OR for current asthma was 20.2 (9.9-41.3) for rBO children with severity score of 6-
12 at two years of age.  
Severity score versus asthma indices 
The predictive capacities for current asthma at 10 years of age (compared to no-BO children) 
assessed by the stringent and loose asthma indices reported by Castro-Rodriguez et al (8) 
were applied to comparable data in the present study (table 4, paper III). Using a cut off 
value six in the present severity score at two years of age gave a higher positive predictive 
value (54.3 %), but similar negative predictive value (86.8 %) compared with the applied 
loose (87.7 %) and stringent indices (87.4 %) (table 4, paper III). 
Bronchial hyper responsiveness 
Children with higher severity scores above five at two years of age had significantly more 
often severe BHR (PD20-methacholine < 1 µmol) compared to subjects with no severity score 
(22.2 % versus 8.5 %, respectively, p=0.0041). On the other hand, subjects with severity 
score above five had significantly less often mild or no BHR (PD20methacholine > 8 µmol) 
compared to children with severity score 0 (44.5 % versus 60.2 %, respectively) (table 5, 
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paper III). 
12.5 Impact of inhaled corticosteroids treatment by two years of age on asthma at 10 
years of age 
Current asthma at 10 years was significantly more frequent among ICS-treated children (56.9 
%) compared to rBO children who were not ICS-treated (30.8 %) and no BO children (5.5 
%) (p<0.001). Among children with current asthma, the rBO children with ICS treatment by 
two years of age versus those without had at two years significantly higher severity scores 
and had significantly more often been admitted to hospital due to BO (paper IV). 
Risk of current asthma at 10 years of age 
Analysis by logistic regression had demonstrated in rBO children that the male gender 
(adjusted OR (aOR): 1.82 (1.01 – 3.27), p=0.046) and severity score at the age of two years 
(aOR 1.14 (1.03 -1.28), p=0.014) were significant risk factors for current asthma at the 10 
years, whereas the use of ICS treatment before two years of age was not significantly 
(borderline) associated with current asthma (aOR 2.00 (0.98 – 4.12), p=0.058) (paper IV). 
Propensity modelling 
To assess current asthma at 10 years of age for rBO children, the propensity modelling was 
used to adjust for severity of disease at two years of age (see section on statistical methods). 
The propensity scores were based upon gender, parental atopy and severity score at two years 
of age. The analysis resulted in a non-significant aOR (95% CI) 1.842 (0.889-3.815), 
(p=0.10), for the use of ICS compared to no use before two years of age. In this model, the 
propensity score at two years of age was significantly associated with current asthma at ten 
years of age (aOR 7.51 (1.70 – 33.21), (p=0.008) (paper IV).                                
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13 GENERAL DISCUSSION 
13.1 Prevalence of childhood asthma, wheeze and allergic sensitization in children 
Prevalence of recurrent bronchial obstruction in 0-2 year old children 
The prevalence of rBO until two years of age was approximately 8.3% of children in the 
present birth cohort study (paper III). The knowledge about prevalence of asthma and 
asthma-related symptoms in children younger than two years of age is limited. A recently 
conducted cross-sectional survey (88) by telephone interviews to parental caretakers of child 
population aged 1-5 years in the USA and Europe found that 32% children have been 
reported to suffer from cough, wheeze or breathlessness in the preceding six months. 
However, the survey was conducted during the winter months, the period when children 
often have infection-triggered wheezing. In this report (88), prevalence varied from 29% in 
Northern Europe to 48% in Southern Europe whereas it was 27% in the USA. Furthermore, 
24% of the interview population (i.e., 8% of the overall population) suffered persistent 
symptoms during the previous six months despite current treatment. The apparent 
discrepancies in the prevalence rates in the study by Bisgaard et al (88) and the present study 
(paper III) could be due to differences in study design, longitudinal versus cross-sectional, 
age range of the children and the time period when they were studied. Our study focused on 
the children from 0 to 2 years of age instead of 1-5 years in the study by Bisgaard et al (88). 
Furthermore, the children in our study had recurrent symptoms of bronchial obstruction in a 
birth cohort population in contrast to the study by Bisgaard et al (88). The results from 
prospective cohort studies are comparatively more reliable and valid when compared to the 
results from cross-sectional surveys. However, more prospective studies are needed to verify 
these findings. 
Prevalence of asthma in school children  
In 10-year-old children in the ECA birth cohort study in Oslo, the prevalence of asthma ever 
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was 20.2 %, doctor’s diagnosis of asthma 16.1%, current asthma 11.1 % and wheeze ever 
30.3% reported in 2005. Asthma prevalence has continued to increase among children in 
Norway since the first report of 0.4% in 1948 (127). Published reports from cross-sectional 
studies in Norway demonstrated lifetime asthma prevalence of 1.77% in 1954 (128), 3.1% in 
1981 (129) to 8% in 1993 (26) and 9.3% in 1994 (28). The three last studies used identical 
questionnaires within Oslo, in contrast to earlier studies which employed different 
questionnaires. The present study indicates more than doubling of prevalence rates over the 
last 10 years until the present finding of 20.2%. This is supported by a repeated cross-
sectional study in Danish school children which has reported doubling of asthma prevalence 
from 1983 to 2001 (130). In a report from ISAAC Phase-III conducted worldwide, Asher and 
co-workers (7) found increasing prevalence of asthma in 6-7 year old children compared to 
13-14 year age-group during the period 2002-3. Furthermore, Pearce and colleagues (8) using 
ISAAC questionnaires found increases in asthma prevalence in Africa, Latin America, and 
parts of Asia indicating that the global burden of asthma is continuing to rise. 
Prevalence of wheeze 
The high prevalence of wheeze ever (30.3 %) reported in 10-year-old Oslo children (paper I) 
is comparable to that of prevalence rates reported in the British studies from the 1990s. 
Furthermore, a cross-sectional study in Norway by Tollefsen and colleagues (21) have shown 
corresponding prevalence rates of current wheeze, 29.0% and 33.5% among girls in age 
groups 13-16 and 17-19 years respectively, and 20.4% and 22.1% among boys in the same 
age group. 
Prevalence of allergic skin sensitization  
The finding of SPT to minimum one allergen in 29.3% of 10 year old children has 
corresponded to one previous Swedish report by Hesselmar and colleagues (131). They 
found positive SPT in 31.7% of 12 -13 year old Swedish children in 1996 with regional 
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variations, 22.5% in Gothenburg to 38.1% in Kiruna (131). However, the prevalence of 
asthma was found to be 8.5% in their study. Hence, our data compared to the Swedish study 
(131) suggest that the increase in prevalence of childhood asthma in Oslo has not been 
accompanied by a parallel increase in allergic sensitization. This is also supported by 
findings in a Danish study conducted 15 years apart (35). 
13.2 Use of inhaled corticosteroids in early childhood 
The extent of use of ICS in young children with asthma or asthma-like symptoms is not well 
known. To our knowledge, the study reported in paper II was the first report of extent of ICS 
use in a prospective follow-up cohort study in very young children. During the study period 
1992-93, 2.1% of all children had received ICS before two years of age, and 21% of all 
children with rBO had at some time by two years of age been treated with ICS. The reported 
use of ICS in infants and young children with rBO in the community of Oslo was likely to be 
representative of the use in the Scandinavian countries at that time.  
An epidemiological study in Japan (132) assessed the use of ICS between 1990 and 2002 and 
information was extracted from the prescription database in four age groups (0-4,5-19,20-39 
and 40-64 years). Authors found that the number of prescriptions for ICS per year increased 
in all age groups except those aged 0-4 years. This might suggest that there might still be 
concerns regarding the efficacy and safety of ICS in this age group, even though reassuring 
studies are available (133). In a Swedish study Wennergren et al (134), there was an 
observed decrease in acute asthma hospitalizations in children > 4 years which was probably 
due to ICS use (based upon prescription statistics). In their study, the hospital admissions for 
acute asthma in those < 4 years, however, had not decreased, but the prescription rates for 
ICS use in this age group was not stated.  
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13.3 Effect of inhaled corticosteroids on lung function in early childhood 
The data presented in paper II, to the authors’ knowledge, is the first study to assess the 
possible modifying effect of ICS on lung function in infants and very young children with 
rBO in a non-interventional, observational prospective cohort. As reported in paper II, we 
found that steroid naïve children with rBO who later received ICS treatment had reduced 
lung function on the first visit (around 11 months of age) compared to those who did not, but 
the differences in lung function disappeared by two years. The positive change in baseline 
tPTEF/tE between the first and second visit among the ICS treated children was positively 
correlated with the duration of inhaled steroid treatment.  
A systematic review by Calpin et al (135) which included 10 randomised double-blind, 
placebo-controlled studies in preschool children concluded that ICS were effective in 
controlling childhood asthma. In infants and young children with recurrent BO after 
admission to hospital due to acute bronchiolitis, several studies demonstrate the beneficial 
effects of ICS (136-138), whereas others did not (139). Teper and colleagues (100) in a 
double-blind RCT of children with recurrent wheezing younger than two years of age found 
that treatment with fluticasone 125 micrograms twice daily for six months improved lung 
function (V’max FRC) and clinical outcomes in children with wheezing compared to group 
treated with placebo. Most of these studies showed effects during the treatment phase. In 
contrast, some recent studies (95;101) have shown lack of effect during the treatment-free 
period. Guilbert and colleagues (95) found improved measures of lung function (derived 
from impulse oscillometry) in preschool children at high risk for asthma during the 
fluticasone treatment phase of two years but the effect had disappeared during the treatment-
free third observation year (95). Murray and co-workers (101) could not find improvement in 
lung function (specific airways resistance, forced expiratory volume in one second and 
airway reactivity) after treatment with fluticasone in preschool children who were 
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prospectively followed for five years.  
Diminished lung function and severity of illness 
In the study reported in paper II, lung function was reduced in the rBO children who later 
received ICS compared to those who remained steroid naïve, and also compared to controls 
at the time of enrolment (mean age 11 months) into the case-control study. To our 
knowledge, this has not been previously reported in children younger than one year of age. 
This finding indicates that children with lower lung function are probably more disposed to 
severe recurrent bronchial obstruction and thereby necessitates the treatment with potent anti-
inflammatory agents like ICS. The findings in paper II further show that inhaled steroids in 
general were given to children with the lowest lung function, albeit the prescribing 
physicians were ignorant of the lung function results. This observation strengthens the 
likelihood that these lung function measures reflect severity of OAD in young children, as 
previously reported (65;108).  
There is potential risk of regression towards mean if extreme values of lung function were 
selected (126) in the study reported in paper II. The analyses demonstrated that this was not 
the case (126). Regression towards mean was also unlikely in view of the marked differences 
between cases and controls in lung function change from the first to the second visit. 
However, it should be noted that the groups of children selected were not on the basis of lung 
function values, but on the treatment received.  
13.4 Severity of obstructive airways disease by two years and later asthma 
Early identification of children at risk of persistent asthma in childhood may improve follow-
up of the children at risk. To explore further how severity of OAD in early life has impact on 
later occurrence of asthma, we have developed a simple severity scoring system for children 
with recurrent bronchial obstruction at two years of age based upon commonly available 
clinical data and no laboratory tests. 
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In the results reported in paper III, a asthma severity score calculated by frequency, 
persistence of BO and hospitalisations for BO during the first two years of life predicted a 
higher risk for current asthma at 10 years of age. The high risk for current asthma at 10 years 
in children with higher severity scores (above five) compared to children with no BO by two 
years of age, exceeds previously published reports (58;59;140). A severity score of five is not 
infrequent in clinical practice, reflecting two hospital admissions with one additional 
obstructive episode or alternatively 5-6 episodes of BO with one month of persisting 
symptoms. 
There were two studies (58;59) in the literature which attempted to predict later 
wheezing/asthma in the children, the first study only after 12 months follow-up (59) whereas 
the second study developed predictive indices to predict asthma beyond one year (58). 
Clough and co-workers (59) in a study of 107 preschool children found that after 12 months 
follow-up of 3-36 months old children, that wheeze was more likely to persist in older, atopic 
infants with parental atopy, and they also detected asthma requiring prophylactic anti-
asthmatic treatment in 49.5 % of the children. In their study (59), among different predictive 
models, the model offering best prediction of persistent wheeze with least risk of including 
asymptomatic subjects was age at presentation and soluble interleukin-2R. 
Severity score versus asthma indices  
The Tucson Children’s Respiratory Study (58), as one of the few studies with reported 
clinical indices based upon the assessment of severity of illness to predict asthma beyond 1-2 
years, employed factors from 0-3 years of age to predict asthma in school age. The loose and 
stringent asthma indices developed by Castro-Rodriguez et al (58) were applied to data 
obtained before three years of age to detect active asthma during one of the surveys between 
six and 13 years of age. The ORs for active asthma at 11 years were 2.6 and 4.3 for the loose 
and the stringent indices respectively (58). In the study reported in paper III, the ORs of 
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current asthma for children with severity score above five compared to children with no BO 
was higher (7.9) than when we applied the loose and stringent (6.4) indices suggested by 
Castro-Rodriguez et al (58). 
Severity score and prognosis 
The predictability of severity score at two years classified by current asthma at ten years was 
demonstrated by a statistically significant area under the curve by the ROC analysis. ROC 
analyses as well as assessment of positive and negative predictive values demonstrate that the 
scoring system can be used to identify children with high and low risk of active asthma in 
later childhood. Consequently, the information obtained in early life may have a prognostic 
value for the patient. Although high severity score can predict later disease, it can not be used 
as a prognostic score as a part of asthma management strategy in order to prevent later 
illness. However, scores to suggest prognosis may be useful to identify children with special 
needs for closer follow-up and the management of disease. 
The simple scoring system based solely upon the history of OAD by two years in paper III, 
may be as suitable to predict current asthma eight years later as the predictive indices (58;59) 
which includes heredity and invasive laboratory tests in this age group. However, compared 
to the severity score at two years of age, a severity score calculated at 12 months of age, 
although a significant risk factor had a poor predictive capability for current asthma nine 
years later. The low predictability of the 12 month severity score in the study reported in 
paper III may reflect that many young children had not yet developed manifestations of 
OAD. However, it should be pointed out that the score at 12 months of age was constructed 
from data obtained in questionnaires only, with less detailed information than that obtained 
during parental interviews at two years of age. 
Severity score and BHR 
The results reported in paper III demonstrate that children with higher severity scores above 
   68 
five by two years of age had significantly more often severe BHR compared to children with 
severity score of 0. To the authors’ knowledge, association between severity of OAD in early 
life and later BHR in children has not been reported previously. To improve our 
understanding of the mechanisms involved between severity of OAD in early life and later 
development of BHR and asthma, more prospective studies are warranted. 
13.5 Early inhaled corticosteroids treatment and prognosis on later asthma 
The main purpose of the study reported in paper IV was to assess if early ICS treatment has 
any effect on disease progression with relation to occurrence of asthma by 10 years of age. 
We found no evidence that early use of ICS in children with rBO during the first two years of 
life reduced the occurrence of current asthma at 10 years of age. To our knowledge, this is 
the first reported risk assessment of early ICS treatment for current asthma eight years later 
in an observational birth cohort study.  
The finding in paper IV that ICS treatment before age two years did not reduce ongoing 
asthma at 10 years of age was supported by three recent RCTs (95;101;141) with ICS 
treatment in early childhood with a follow-up to three and five years of age. Guilbert et al 
(95) studying high risk children (positive asthma predictive index) reported significant 
improvement in lung function measures during two years treatment with inhaled fluticasone 
propionate 88 µg twice daily compared to placebo. However, during the third treatment-free 
year, there was no longer any improvement either in asthma symptoms or exacerbations or 
lung function (95). Murray and colleagues (101) in a birth cohort treated 200 children with 
fluticasone 100 µg twice daily or placebo and attempted three monthly treatment reductions 
before eventual cessation of ICS treatment. After a follow-up until five years of age, the 
authors found no effect of fluticasone on the natural history of asthma, lung function decline 
or airways reactivity after stopping treatment (101). In the study of Bisgaard et al (141) of 
high risk infants from one month of age, daily treatment of 400 µg budesonide for two weeks 
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intermittently during wheezy episodes or cough was no better than placebo to prevent 
persistent wheeze at three years of age. Two of these studies introduced treatment early 
(101;141), whereas Guilbert et al (95) started treatment after two years of age. The treatment 
strategies also differed in the three studies: two years continuous ICS treatment in the study 
by Guilbert et al (95), a step-up/step-down strategy in the study by Murray et al (101) and 
short courses of ICS in the study by Bisgaard et al (141). In contrast to these studies 
(95;101;141), the ICS treatment in the present observational and non-interventional study 
was decided by their regular physicians based on clinical symptoms (paper IV).  
The protocol for all these trials (95;101;141) and the study reported in paper IV differs in 
several aspects. However, the negative results provide additional, non-overlapping evidence 
that ICS do not change the natural course of asthma. The fact that the long term results of all 
these studies with respect to asthma prevention were identical in spite of their disparate target 
populations and treatment strategies allows for reasonably definitive conclusions. However, 
apart from the study of Guilbert et al (95), Murray et al (101) and the present study (paper 
IV), little information of long-term effects of ICS treatment during the first few years of life 
is reported.  
The concept of inflammatory remodelling in early childhood is still unclear as reticular 
basement membrane thickening and the eosinophilic inflammation characteristic of asthma in 
older children and adults have not been found in symptomatic children below three years of 
age with reversible airflow obstruction (80). Moreover, evidence of persistent inflammation 
despite inhaled corticosteroid therapy has been reported in adults (142) and adolescents 
despite asthma in remission (143).  
Factors in early life associated with more severe disease are both risk factors for persisting 
disease (paper III), as well as for starting ICS treatment. Although subjects who received ICS 
treatment by two years had more severe disease, the propensity score was used to adjust for 
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the severity of the disease between 0-2 years of age. The propensity approach underlined the 
result found with a conventional analysis.  
13.6 Strengths and limitations of the present studies 
Strengths  
The strength of the present birth cohort is the detailed and well described population that has 
been followed for 10 years with a design especially suited for investigating asthma and 
asthma phenotypes. Furthermore, the present cohort includes a large population of children 
with lung function measurements shortly after birth.  
The results reported in papers III and IV are from children enrolled in nested case-control 
design at two years of age, a part of an observational prospective cohort of healthy newborn 
children. This study with a follow-up rate of 89 % at 10 years of age is based on an urban, 
unselected birth cohort, with early identification of OAD as well as children with no lower 
respiratory disease before two years of age. The children were prospectively followed from 
birth to two years with six monthly questionnaires to increase the reliability of data and 
thereby limiting the risk of recall bias for the first two years. The study has focused on 
clinical presentation at the time of investigation (two and 10 years), rather than the 
retrospective categorization of “wheezing” phenotypes such as early onset transient wheeze, 
persistent wheeze and late onset wheeze (3;40), which in our view is more appropriate to do 
in such study. 
Clinical examinations of all children were performed by study doctors with experience in 
paediatric pulmonology and allergology. The clinical assessments can therefore be regarded 
as reliable and consistently reported. 
In papers I, III and IV, current asthma was defined by combining clinical diagnosis, 
symptoms and medication and a physiological objective measure of BHR increasing the 
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likelihood of selecting children with true persistent asthma and ongoing inflammatory 
airways disease. Furthermore, we chose to define asthma more strictly than a doctor’s 
diagnosis alone, or by questionnaire-reported wheeze. This is in contrast to other published 
studies where symptoms and/or treatment alone were used to define current asthma. Thus, a 
detailed structured interview and the requirement of at least two out of three commonly used 
criteria reduce the risk for both over- and under- diagnosis of asthma and improve the quality 
of asthma diagnosis.  
The design of the study ensured that treatment was decided by the child’s own doctor, 
independent of the study doctors, thus avoiding the risk of observational bias in the treatment 
assignment (paper II and IV).  
Limitations 
In the observational data sets presented in the paper IV, we could not separate the influence 
of the start of treatment from the effect of the duration of treatment. Subjects with severe 
disease are more likely to receive treatment and more likely to have a worse outcome. 
Propensity score methodology is useful in an observational study like the present (paper IV) 
and in situations where a RCT is not feasible (144). The purpose of the propensity score is to 
adjust for disease severity, and it is therefore important, to explore a number of possible 
propensity models and achieve a model that accurately predicts treatment assignment in order 
to avoid selection bias (125). The propensity modelling has been recommended by the United 
States Food and Drug Administration (FDA) for use in non-randomised trials, to compensate 
for the problem that patients are not randomly assigned to treatment groups with equal 
probability (124). The results from these two types of studies (RCT and cohort study) 
complement each other. On one hand, the results from a non-randomised observational study 
may generate a hypothesis and may provide useful supportive data but long term RCTs will 
be needed to confirm such findings. On the other hand, prospective cohort studies can also be 
   72 
useful to confirm the findings from RCTs. 
The results from RCTs has highest level of evidence (Evidence category A) when compared 
to observational studies (Evidence C) as reported by GINA (3). Although RCTs are generally 
considered the best study designs to assess treatment efficacy, they however are associated 
with high costs, selected populations with stringent inclusion and exclusion criteria tailored 
to the medicament studied and are often logistically difficult to maintain for many years. In 
contrast to RCTs, the advantages of observational cohort studies are that they reflect ‘real 
life’ clinical practice and includes broader population of participants in the absence of 
disease-related exclusion criteria (145). For medical practice, the results from longitudinal 
observational studies are reliable especially concerning diagnosis and prognosis (146). 
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14 CONCLUSIONS 
1) The prevalence of recurrent bronchial obstruction in young children by two years of age 
was 8.3 % in the present birth cohort.  
Furthermore, every fifth 10 year old child in the city of Oslo at some time had asthma. Our 
finding of 20.2 % lifetime prevalence of asthma among 10-year-old children represents the 
highest number ever reported in Scandinavia. However, the observed increase in asthma 
prevalence in this cohort study was not accompanied by parallel increase in allergic 
sensitization.  
2) The extent of use of ICS (reported by parents) corresponded to 2.1 % of all children in the 
cohort study followed until two years of age and 21 % of children with recurrent bronchial 
obstruction by two years of age.  
3) The rBO children who received subsequent ICS treatment had reduced lung function 
compared to those who remained steroid naïve at debut of obstructive airways disease. Lung 
function improved in children using ICS until two years of age, mostly in children with the 
longest duration of treatment. It suggests that ICS treatment once started has a disease 
modifying effect with relation to lung function in young children. This factor should, 
therefore, also be taken into consideration when addressing the effects of environmental 
factors upon lung function. 
4) A scoring system based on severity and frequency of obstructive airways disease during 
the first two years of life predicted a higher risk for current asthma at 10 years of age. The 
simplicity of the symptom score renders it generally applicable for early identification and 
follow-up of children at high risk for persistent asthma. Furthermore, the children with high 
severity score (above five) by two years of age had significantly more often severe BHR 
(PD20-metacholine < 1 µmol) at 10 years of age than children with a lower or 0 score.  
5) A mean of nine months treatment with ICS in children with obstructive airways disease 
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before the age of two years does not seem to reduce the occurrence of asthma at 10 years of 
age, but larger intervention studies are needed to confirm this finding. Although early use of 
ICS has been shown to have short term beneficial effects, the results presented in paper IV 
study does not support the hypothesis of improved long term prognosis for children treated 
with inhaled corticosteroids for recurrent bronchial obstruction in early life. Thus, the 
possible role of ICS treatment as a disease modifier in the development of asthma in children 
is yet to be ascertained.  
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ERRATA 
 
The following changes have been made from the thesis originally submitted to the Doctoral 
Committee: 
1. List of Papers, page 7: updated reference of Paper III. Since submission to the 
Doctoral Committee, paper III has been published in Thorax which is now included 
as a part of thesis. There are no changes between the online version that was 
originally submitted and the final published version. 
2. Replaced “six” with “five” on page 44, line 5. 
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PAPERS I - IV  
